Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...
Does Medicare cover Leqembi?
Medicare Part B covers Leqembi for people with early Alzheimer's or mild cognitive impairment. Learn more about Leqembi and Medicare coverage here.
"LEQEMBI®" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
Biogen expects steady growth for Alzheimer's drug Leqembi in near term
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States ...
The Register-Herald17h
Rockefeller Neuroscience Institute expands access to groundbreaking Alzheimer’s treatment
The WVU Rockefeller Neuroscience Institute (RNI) is providing patients greater statewide and regional access to a ...
Morningstar9d
Leqembi® approved in Mexico
Leqembi selectively binds to soluble amyloid-beta (Aβ) aggregates (protofibrils2), as well as insoluble Aβ aggregates (fibrils) which are a major component of Aβ plaques in Alzheimer's disease ...
Benzinga.com5d
Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown
Biogen faces potential earnings drop of 20-30% by 2030 due to Ocrevus biosimilar competition. Leqembi (lecanemab) sales growth remains sluggish, falling below consensus projections through 2030.
Yahoo Finance9d
Leqembi® approved in Mexico
STOCKHOLM, Dec. 5, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) ...
Medindia10d
Leqembi® approved in Mexico
STOCKHOLM, Dec. 4, 2024 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk ...